By Associate Professor Hao-Wen Sim

Journal articles

Doherty MK; Tam VC; McNamara MG; Jang R; Hedley D; Chen E; Dhani N; Tang P; Sim HW; O’Kane GM; DeLuca S; Wang L; Pedutem T; Knox JJ, 2022, 'Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer', British Journal of Cancer, 127, pp. 1473 - 1478, http://dx.doi.org/10.1038/s41416-022-01903-6

Kong BY; Sim HW; Barnes EH; Nowak AK; Hovey EJ; Jeffree R; Harrup R; Parkinson J; Gan HK; Pinkham MB; Yip S; Hall M; Tu E; Carter C; Koh ES; Lwin Z; Dowling A; Simes JS; Gedye C, 2022, 'Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma', BMJ Open, 12, http://dx.doi.org/10.1136/bmjopen-2021-058107

Kong BY; Carter C; Nowak AK; Hovey E; Lwin Z; Haghighi N; Gan HK; Sim HW; Ziegler DS; Barton K; Parkinson J; Leonard R; Khasraw M; Foote M, 2022, 'Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective', Asia Pacific Journal of Clinical Oncology, 18, pp. 259 - 266, http://dx.doi.org/10.1111/ajco.13606

Krasovitsky M; Lee YC; Sim HW; Chawla T; Moore H; Moses D; Baker L; Mandel C; Kielar A; Hartery A; O'Malley M; Friedlander M; Oza AM; Wang L; Lheureux S; Wilson M, 2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319

Sim HW; Galanis E; Khasraw M, 2022, 'PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities', Cancers, 14, http://dx.doi.org/10.3390/cancers14041003

Malone ER; Sim HW; Stundzia A; Pierre S; Metser U; O’Malley M; Sacher AG; Sridhar SS; Hansen AR, 2022, 'Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma', Canadian Urological Association Journal, 16, http://dx.doi.org/10.5489/CUAJ.7467

Matsuyama M; Sachchithananthan M; Leonard R; Besser M; Nowak AK; Truran D; Vajdic CM; Zalcberg JR; Gan HK; Gedye C; Varikatt W; Koh ES; Kichenadasse G; Sim HW; Gottardo NG; Spyridopoulos D; Jeffree RL, 2022, 'What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry', Neuro Oncology Practice, 9, pp. 68 - 78, http://dx.doi.org/10.1093/nop/npab055

Kong BY; Sim HW; Nowak AK; Yip S; Barnes EH; Day BW; Buckland ME; Verhaak R; Johns T; Robinson C; Thomas MA; Giardina T; Lwin Z; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Hovey EJ; Cher LM; Kichendasse G; Khasraw M; Hall M; Tu E; Amanuel B; Koh ES; Gan HK, 2021, 'LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study', BMJ Open, 11, http://dx.doi.org/10.1136/bmjopen-2021-054075

Field KM; Barnes EH; Sim HW; Nowak AK; Simes J; Rosenthal MA; Wheeler H; Hovey EJ; Cher LM, 2021, 'Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial', Journal of Clinical Neuroscience, 94, pp. 321 - 327, http://dx.doi.org/10.1016/j.jocn.2021.10.022

Kong B; Sim H-W; Amanuel B; Day B; Buckland M; Verhaak R; Yip S; Johns T; Lwin Z; Rosenthal M; Nowak AK; Barnes EH; Scott AM; Parkinson J; Jeffree R; De Abreu Lourenco R; Lau P; Whittle J; Hovey E; Cher L; Kichendasse G; Hall M; Robinson C; Thomas M; Giardina T; Tu E; Khasraw M; Koh E-S; Gan H, 2021, 'INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY', Neuro-Oncology, 23, pp. vi106 - vi107, http://dx.doi.org/10.1093/neuonc/noab196.420

Kong B; Sim H-W; Koh E-S; Gan H; Barnes EH; Yip S; Nowak AK; Lau P; Cuff K; Khoo E; Lwin Z; Cooper A; Dowling A; Linton A; Harrup R; Dunlop T; Hovey E; Parkinson J; Jeffree R; Hall M; Tu E; Andrew D; Simes J; Gedye C, 2021, 'RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL', Neuro-Oncology, 23, pp. vi193 - vi194, http://dx.doi.org/10.1093/neuonc/noab196.767

Sim HW; Nowak AK; Lwin Z; Khasraw M, 2021, 'Management of glioblastoma: An Australian perspective', Chinese Clinical Oncology, 10, http://dx.doi.org/10.21037/cco.2020.02.05

Floros P; Rao A; McCloy RA; Sim HW; Chin VT; Leavers BC; Crawford JA; Gallagher RM, 2021, 'Altered presentation of oropharyngeal cancer, a 6-year review', ANZ Journal of Surgery, 91, pp. 1240 - 1245, http://dx.doi.org/10.1111/ans.16537

Hecht JR; Lonardi S; Bendell J; Sim HW; Macarulla T; Lopez CD; van Cutsem E; Muñoz Martin AJ; Oh Park J; Greil R; Wang H; Hozak RR; Gueorguieva I; Lin Y; Rao S; Ryoo BY, 2021, 'Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)', Journal of Clinical Oncology, 39, pp. 1108 - 1118, http://dx.doi.org/10.1200/JCO.20.02232

Parmar A; Qazi AA; Stundzia A; Sim HW; Lewin J; Metser U; O'Malley M; Hansen AR, 2021, 'Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer', Canadian Urological Association Journal, 16, http://dx.doi.org/10.5489/CUAJ.7294

Jiang DM; Sim HW; Espin-Garcia O; Chan BA; Natori A; Lim CH; Moignard S; Chen EX; Liu G; Darling G; Swallow CJ; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW; Elimova E, 2021, 'Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer', Oncology Switzerland, 99, pp. 49 - 56, http://dx.doi.org/10.1159/000510446

Lamb LS; Sim HW; McCormack AI, 2020, 'Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy', Frontiers in Endocrinology, 11, pp. 576027, http://dx.doi.org/10.3389/fendo.2020.576027

Agar M; Nowak A; Hovey E; Barnes E; Simes J; Vardy J; Wheeler H; Leonard R; Hall M; Tim E; Spyridopoulos D; Sim H-W; Lwin Z; Dowling A; Harrup R; Jennens R; Kichenadasse G; Dunlop T; Gzell C; Koh E-S, 2020, 'QOLP-23. PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE', Neuro-Oncology, 22, pp. ii179 - ii180, http://dx.doi.org/10.1093/neuonc/noaa215.748

Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC, 2020, 'Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European Urology Oncology, 3, pp. 530 - 539, http://dx.doi.org/10.1016/j.euo.2020.01.001

Hallal S; Khani SE; Wei H; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL, 2020, 'Deep sequencing of small RNAs from neurosurgical extracellular vesicles substantiates miR-486-3p as a circulating biomarker that distinguishes glioblastoma from lower-grade astrocytoma patients', International Journal of Molecular Sciences, 21, pp. 1 - 22, http://dx.doi.org/10.3390/ijms21144954

Hallal S; Azimi A; Wei H; Ho N; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL, 2020, 'A comprehensive proteomic SWATH-MS workflow for profiling blood extracellular vesicles: A new avenue for glioma tumour surveillance', International Journal of Molecular Sciences, 21, pp. 1 - 26, http://dx.doi.org/10.3390/ijms21134754

Alghamdi MA; Amaro CP; Lee-Ying R; Sim HW; Samwi H; Chan KK; Knox JJ; Ko YJ; Swiha M; Batuyong E; Romagnino A; Cheung WY; Tam VC, 2020, 'Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database', Cancer Medicine, 9, pp. 4918 - 4928, http://dx.doi.org/10.1002/cam4.3228

Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R, 2020, 'Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab', Cancer Medicine, 9, pp. 4640 - 4647, http://dx.doi.org/10.1002/cam4.3116

Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim HW; Natori A; Chan BA; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW; Elimova E, 2020, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma', Cancer Medicine, 9, pp. 3023 - 3032, http://dx.doi.org/10.1002/cam4.2948

Ma LX; Espin-Garcia O; Lim CH; Jiang DM; Sim HW; Natori A; Chan BA; Suzuki C; Chen EX; Liu G; Brar SS; Swallow CJ; Yeung JC; Darling GE; Wong RK; Kalimuthu SN; Conner J; Elimova E; Jang RW, 2020, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers', Journal of Gastrointestinal Oncology, 11, pp. 356 - 365, http://dx.doi.org/10.21037/jgo.2020.03.03

Lamb LS; Sim HW; McCormack AI, 2020, 'Exploring the role of novel medical therapies for aggressive pituitary tumors: A review of the literature—“are we there yet?”', Cancers, 12, pp. 308, http://dx.doi.org/10.3390/cancers12020308

Ma LX; Sun P; Espin-Garcia O; Suzuki C; Jiang DM; Lim CH; Taylor K; Chan BA; Sim H-W; Natori A; Chen EX; Liu G; Knox JJ; Yeung J; Darling GE; Kim J; Kalimuthu S; Elimova E; Jang RW-J, 2020, 'Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field.', Journal of Clinical Oncology, 38, pp. 328 - 328, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.328

Feng S; Sim H-W; Bucur R; Aggarwal R; Abreu P; Ray M; Herman M; Cheng D; Chen Z; Zhang W; Greig PD; Wei AC-C; Moulton C-A; McGilvray IM; Cleary SP; Gallinger S; Sapisochin G; Knox JJ; Liu G; Chen EX, 2020, 'Preoperative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC).', Journal of Clinical Oncology, 38, pp. 571 - 571, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.571

Hecht JR; Lonardi S; Bendell JC; Sim H-W; Macarulla T; Lopez CD; Van Cutsem E; Martin AJM; Park JO; Greil R; Lin Y; Rao S; Ryoo B-Y, 2020, 'Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).', Journal of Clinical Oncology, 38, pp. 637 - 637, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.637

Stukalin I; Wells JC; Fraccon A; Pasini F; Porta C; Lalani A-KA; Srinivas S; Bowman IA; Brugarolas J; Lee J-L; Donskov F; Beuselinck B; Bamias A; Rini BI; Sim H-W; Agarwal N; Rha S-Y; Kanesvaran R; Choueiri TK; Heng DYC, 2020, 'Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) (vol 2, pg 31, 2018)', KIDNEY CANCER, 4, pp. 119 - 119, http://dx.doi.org/10.3233/KCA-200005

Khasraw M; McDonald KL; Rosenthal M; Lwin Z; Ashley D; Wheeler H; Barnes E; Foote M; Koh E-S; Sulman E; Back M; Buckland M; Sim H-W; Fisher L; Leonard R; Hall M; Yip S; Simes J, 2019, 'ACTR-24. A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY', Neuro-Oncology, 21, pp. vi18 - vi18, http://dx.doi.org/10.1093/neuonc/noz175.067

Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX, 2019, 'Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase mutations in gliomas', Clinical Cancer Research, 25, pp. 3366 - 3373, http://dx.doi.org/10.1158/1078-0432.CCR-18-3205

Ma LX; Espin-Garcia O; Lim CH; Sun P; Jiang DM; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Suzuki C; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2019, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.', Journal of Clinical Oncology, 37, pp. 4069 - 4069, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4069

Herman M; Zhang Y; Wang L; Sim H-W; Knox JJ, 2019, 'Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e15645

Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW-J; Elimova E, 2019, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e15579

Kroeger N; Li H; De Velasco G; Donskov F; Sim H-W; Stuehler V; Wells JC; Stukalin I; Heide J; Bedke J; Agarwal N; Parekh H; Rini B; Knox EJ; Pantuck A; Choueiri TK; Heng DYC, 2019, 'Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies', CLINICAL GENITOURINARY CANCER, 17, pp. 65 - 71, http://dx.doi.org/10.1016/j.clgc.2018.09.006

Ma LX; Espin-Garcia O; Lim CH; Sun P; Jiang DM; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Suzuki C; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2019, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.164

Taylor K; Espin-Garcia O; Jiang DM; Yokom D; Xiaolu L; Lim CH; Chan BA; Sun P; Sim H-W; Natori A; Liu G; Darling GE; Wong R; Chen EX; Jang RW-J; Veit-Haibach P; Rozenberg D; Elimova E, 2019, 'Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.', Journal of Clinical Oncology, 37, pp. 171 - 171, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.171

Fung AS; Tam VC; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY; Samawi H; Lee-Ying RM, 2019, 'Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).', Journal of Clinical Oncology, 37, pp. 422 - 422, http://dx.doi.org/10.1200/jco.2019.37.4_suppl.422

Jiang DM; Suzuki C; Espin-Garcia O; Pintilie M; Lim CH; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Yokom D; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW-J; Elimova E, 2019, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.162

Fung AS; Lee-Ying RM; Meyers DE; Sim H-W; Knox JJ; Zaborska VO; Davies JM; Ko Y-J; Batuyong E; Cheung WY; Samawi H; Tam VC, 2019, 'Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.438

Natori A; Chan BA; Sim HW; Ma L; Yokom DW; Chen E; Liu G; Darling G; Swallow C; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox J; Elimova E; Jang RW, 2018, 'Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer', Current Oncology, 25, pp. 366 - 370, http://dx.doi.org/10.3747/co.25.4208

Nejad R; Nassiri F; Mamatjan Y; Sim H-W; Chen E; Agnihotri S; Aldape K; Zadeh G, 2018, 'CBMT-06. LOWER GRADE ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS METABOLICALLY MIMICKING GLIOBLASTOMA (GBM) EXPRESS HIGHER R:S 2-HYDROXYGLUTARATE RATIOS RELATIVE TO NON-GBM-MIMICKING IDH MUTANT GLIOMAS', Neuro-Oncology, 20, pp. vi33 - vi33, http://dx.doi.org/10.1093/neuonc/noy148.125

Mitchell L; Tam S; Lewin J; Srikanthan A; Heck C; Hodgson D; Vakeesan B; Sim HW; Gupta A, 2018, 'Measuring the impact of an adolescent and young adult program on addressing patient care needs', Journal of Adolescent and Young Adult Oncology, 7, pp. 612 - 617, http://dx.doi.org/10.1089/jayao.2018.0015

Meyers DE; Lee-Ying R; Alghamdi M; Sim H-W; Zaborska VO; Ko Y-J; Raycraft T; Batuyong E; Cheung WY; Samawi H; Davies JM; Tam VC, 2018, 'Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database', ANNALS OF ONCOLOGY, 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277301285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC, 2018, 'Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', Cancer, 124, pp. 3677 - 3683, http://dx.doi.org/10.1002/cncr.31595

Samawi HH; Sim HW; Chan KK; Alghamdi MA; Lee-Ying RM; Knox JJ; Gill P; Romagnino A; Batuyong E; Ko YJ; Davies JM; Lim HJ; Cheung WY; Tam VC, 2018, 'Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database', Cancer Medicine, 7, pp. 2816 - 2825, http://dx.doi.org/10.1002/cam4.1493

Natori A; Sim H-W; Chan BA; Sun P; Moignard S; Yokom D; Lim CH; Jiang DM; Ma LX; Chen EX; Liu G; Knox JJ; Darling GE; Yeung JC-W; Wong R; Hafezi-Bakhtiari S; Conner J; Rogalla P; Jang RW-J; Elimova E, 2018, 'Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 36, pp. 4066 - 4066, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.4066

Lim CH; Yokom D; Jiang DM; Ma LX; Sun P; Sim H-W; Natori A; Chan BA; Moignard S; Knox JJ; Chen EX; Liu G; Swallow CJ; Darling GE; Brar SS; Hafezi-Bakhtiari S; Conner J; Elimova E; Jang RW-J, 2018, 'Outcomes for advanced HER2 positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.', Journal of Clinical Oncology, 36, pp. e16069 - e16069, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e16069

Doherty M; Tam VC; McNamara MG; Hedley DW; Dhani NC; Chen EX; Jang RW-J; Tang PA; Sim H-W; O'Kane GM; DeLuca S; Wang L; Brooks K; Knox JJ, 2018, 'Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.', Journal of Clinical Oncology, 36, pp. 4084 - 4084, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.4084

Back to profile page